SPRAVATO: payments to doctors
Payments that named SPRAVATO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $30.2M
- Providers
- 47,057
- Transactions
- 244,046
- Average per transaction
- $124
The per-transaction average — $124 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 47,057 providers the average total is $641, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $27,614,037 | 91.5% |
| Janssen Scientific Affairs, LLC | $2,233,591 | 7.4% |
| Janssen Research & Development, LLC | $202,675 | 0.7% |
| Janssen Global Services, LLC | $116,348 | 0.4% |
| Johnson & Johnson Surgical Vision, Inc. | $17 | 0.0% |